Compare PRZO & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRZO | CMND |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 2.6M |
| IPO Year | 2022 | 2021 |
| Metric | PRZO | CMND |
|---|---|---|
| Price | $0.71 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 317.2K |
| Earning Date | 03-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.07 |
| 52 Week High | $1.90 | $4.66 |
| Indicator | PRZO | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 25.38 |
| Support Level | $0.66 | $0.59 |
| Resistance Level | $0.82 | $1.27 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 20.04 | 0.60 |
ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.